| Name | Title | Contact Details |
|---|
Aledade is a new company with an old-fashioned goal: putting doctors back in control of health care. Aledade partners with independent, primary care physicians to provide everything the doctors need to create and run an Accountable Care Organization (ACO) – from business and practice transformation services to upfront capital and a cutting-edge technology platform. Our customized solutions – and our continuous, on-the-ground support of our physician partners – will help doctors in all types of communities across America preserve their autonomy, deliver better care to their patients, reduce overall costs, and keep independent physician practices flourishing.
Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Flagship Pioneering is an American life sciences venture capital company based in Cambridge, Massachusetts that invests in biotechnology, life sciences, health and sustainability companies.
We are pleased to offer clinicians the first of many advances, the GI-MAP™. The GI-MAP™ (GI-Microbial Assay Plus) stool test utilizes cutting edge, FDA-approved technology to provide a true DNA/PCR based stool analysis which provides actionable informa...
The trillions of microbes that call us home – the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta Biosciences is developing an innovative class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta Biosciences was co-founded by PureTech and a group of world renowned experts in immunology and microbiology.